Home
Storia in 4 fonti
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
- ·
cnbc.com
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
- ·
ansa.it
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Seduta pesante per la multinazionale danese del farmaco Novo Nordisk dopo aver reso pubblici dati deludenti sulla sperimentazione della terapia antiobesità Cagrisema. (ANSA)
